Slingshot members are tracking this event:

Merck Acquires IOmet Pharma, a privately-held UK-based drug discovery company focused on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and metabolism

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Management Comment “The acquisition of IOmet is a further example of Merck’s commitment to fully realizing the potential of this rapidly evolving field through our existing innovative portfolio as well as the acquisition of promising immunotherapeutic candidates.” “Merck’s leadership in immuno-oncology and expertise in development combined with the potential of our IDO1 and TDO programs creates significant opportunity for us to advance the treatment of cancer,” said Alan Wise, Ph.D., CEO, IOmet.
Additional Relevant Details Financial terms of the acquisition were not disclosed.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Acquisition, Transaction, Drug Discovery, Metastatic Non-small Cell Lung Cancer, Cancer Immunotherapy Platform, Metabolism